Literature DB >> 7761353

The role of 80K/MARCKS, a specific substrate of protein kinase C, in cell growth and tumour progression.

G Brooks1.   

Abstract

Since its discovery more than a decade ago [Wu et al., 1982; Rozengurt et al., 1983], the 80-87 kDa myristoylated alpha lanine-rich C-kinase substrate (80K/MARCKS) protein has attracted a great deal of attention from researchers interested in cell growth and tumour progression. However, despite its ubiquitous distribution, a definitive functional role for 80K/MARCKS has not been found. The purpose of this review is to describe the properties, distribution and regulation of 80K/MARCKS and to discuss some of the most recent findings, both from our laboratory and from others, that have suggested a functional role for this protein in modulating cell growth and tumour progression. Furthermore, I will present data from our laboratory that implicates 80K/MARCKS as a novel tumour suppressor in cells of melanocyte origin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7761353     DOI: 10.1111/j.1600-0749.1994.tb00074.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  3 in total

1.  MARCKS-like protein, a membrane protein identified for its expression in developing neural retina, plays a role in regulating retinal cell proliferation.

Authors:  Jing Zhao; Tomonori Izumi; Kazuto Nunomura; Shinya Satoh; Sumiko Watanabe
Journal:  Biochem J       Date:  2007-11-15       Impact factor: 3.857

2.  Identification of single and double sites of phosphorylation by ECD FT-ICR/MS in peptides related to the phosphorylation site domain of the myristoylated alanine-rich C kinase protein.

Authors:  Kellie A Woodling; John R Eyler; Yury O Tsybin; Carol L Nilsson; Alan G Marshall; Arthur S Edison; Iman M Al-Naggar; Michael R Bubb
Journal:  J Am Soc Mass Spectrom       Date:  2007-09-20       Impact factor: 3.109

3.  Overexpression of MARCKS indicates a poor prognosis of oral squamous cell carcinoma.

Authors:  Chengjing Li; Rong Xia; Haowei Xue; Yukun Hu; Ming Sun; Dongdong Fang; Wenyu Yang; Feng Xiao; Jun Hou
Journal:  Oncol Lett       Date:  2018-08-16       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.